Trial Profile
Dyslipidemia in Type 2 Diabetes (0767-034)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0767 (Primary) ; Glipizide; Pioglitazone
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 02 Mar 2014 New trial record